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SHORT REPORT
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Between 1970 and 2003, seven cases of human dura mater-
associated Creutzfeldt–Jakob disease (CJD) were identified in
the UK. Furthermore, we identified a case of CJD in a porcine
dura graft recipient. The mean incubation period of the
human dura mater cases was 93 (range 45–177) months.
The clinico-pathological features of the cases are described
and compared with cases previously reported in the world
literature.
C
reutzfeldt–Jakob disease (CJD) exists in four clinical
forms: sporadic, genetic, iatrogenic and variant. The
cause of sporadic CJD, the most common form world-
wide, is unknown and case–control studies have failed to
identify any consistent risk factor, although two studies have
implicated previous surgical interventions.1 2 Genetic forms of
the disease are associated with underlying mutations of the
prion protein gene (PRNP), which are generally considered to
be directly causative. Mutations, however, possibly increase
liability to some, as of yet unrecognised, source of infection.
The two remaining forms of CJD are acquired. Variant CJD is
considered to be caused by bovine spongiform encephalo-
pathy through contaminated food products3–5; iatrogenic CJD
results from the inadvertent transmission of CJD during the
course of medical or surgical treatment. The two most
numerically significant instances of iatrogenic CJD resulted
from treatment with cadaveric human growth hormone and
the use of dura mater grafts in surgery. Corneal grafts, depth
electrodes and neurosurgical instruments have also rarely
been implicated.6 7
The first report of dura mater-associated CJD was
published in 1987,8 with a more detailed report appearing
the following year;9 to date, 164 cases have been recognised
worldwide (P Brown, personal communication, 2006). This
paper reports and describes the seven cases of human dura
mater graft-associated CJD identified during surveillance in
the UK and, for the first time, reports a case of CJD in a
porcine dura graft recipient.
METHODS
CJD surveillance in the UK has been undertaken in four
phases.
N A retrospective review in England and Wales from 1970 to
1979.
N A prospective study in England and Wales from 1980 to
1984.
N A retrospective review in the UK to cover the period from
1985 to 1990.
N A prospective surveillance was instituted in the UK in 1990
and continues.
The methodology of the National CJD Surveillance Unit
has been described in previous publications.10 11
RESULTS
Human dura mater
During the period 1970 and 2003, seven cases of human dura
mater-associated CJD were identified in the UK (table 1). The
latent period between surgery and the onset of CJD ranged
from 45 to 177 months* (mean 93). The mean age at surgery
was 33 years, with a mean age at onset of 41 years.
Lyodura (B Braun Melsungen, Germany), a particular
brand of human dura mater, was implicated in six of the
seven cases (the manufacturer of the dura graft implicated in
case I is unknown).
The six cases associated with Lyodura were exposed to the
presumed source of ‘‘infection’’ between 1983 and 1987, with
the first recognised case in the UK exposed to human dura
mater in 1969.
A detailed account of both clinical and investigative
features is available at http://jnnp.bmjjournals.com/
supplemental. In four cases, the clinical phenotype at onset
appears to correlate with the site of graft placement or
underlying parenchymal damage (cases II, III, V and VI). For
example—in case II, the presenting clinical features included
a right visual field defect in an individual with a tumour
localised to the left hemisphere. The subsequent CJD began
with a right visual field disturbance and progressed with
signs indicating the involvement of the left hemisphere.
Some of the cases were investigated before the widespread
availability of MRI; therefore MRI was available in only four
of the seven cases. None of the cases showed the character-
istic radiological features of human prion disease14 with post-
surgical change being the most commonly recognised
abnormality. Despite all seven cases having at least one
electroencephalogram during the course of investigation,
only three of the seven cases showed the ‘‘typical’’ features.
Autopsy was carried out in five of the seven cases. In
general, the neuropathology was characterised by widespread
spongiform change accompanied by variable neuronal loss
and gliosis. Western blot analysis for PrPres was carried out in
three cases (II, VI and VII). The mobility and glycoform ratio
of the PrPres is indistinguishable from those of type 1 PrPres
identified in cases of sporadic CJD, and is distinct from type
2B PrPres identified in variant CJD.
Porcine dura mater
We believe the identification of CJD in a porcine graft
recipient to be the first such report worldwide (table 1,
case VIII). The recipient underwent excision of a right
fronto-parietal meningioma in 1988 and a zenoderm graft
was used to repair the dura. The recipient presented with
*Case V received two dura grafts, it is assumed that the first graft was
responsible for transmission.
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headaches, ataxia and cognitive decline 134 months later.
Investigative features, including an electroencephalogram,
were supportive of the clinical diagnosis, and pathological
confirmation was obtained. Autopsy showed spongiform
change in the frontal and temporal cortex, with similar
features identified in the basal ganglia, thalamus and
cerebellum. Immunocytochemistry for PrP showed wide-
spread accumulation and western blot analysis showed the
type 1 isoform.
DISCUSSION
Human dura mater is a rare, but important source of
transmission of human prion disease, with only seven cases
recognised in a 33-year period. Surveillance systems world-
wide have identified 164 cases of CJD in people previously
exposed to human dura mater. Prevalence is particularly high
in Japan and probably reflects neurosurgical practice, with an
estimated 20 000 grafts used each year.15 The overall risk of
CJD associated with human dura grafts in the UK is
unknown because an accurate estimation of human dura
graft use and thus a denominator for calculation of risk is not
available. The estimated risk after exposure in Japan has
been estimated to be approximately 1 per 2000 patients
treated between 1979 and 2000 and approximately 1 per 1000
between 1983 and 1987.16 Neurosurgical practice in Japan,
with widespread use of dura mater, may be different from
other countries throughout the industrialised world and
therefore it is unreasonable to extrapolate any estimated risk
from these data. If neurosurgical practices in the UK were
more akin to those in Australia, then a subsequent study by
Brooke and co-workers would help provide additional
information pertaining to estimated risk. By using informa-
tion from the Australian CJD Surveillance system, Brooke
and co-workers estimated the risk associated with exposure
to human dura mater to be approximately 1 per 500 patients
treated between 1978 and 2003.17 Clearly, the risk of
developing CJD in this patient population is considerably
higher than we would expect by chance.
The human dura mater implicated in the transmission of
CJD was processed, almost exclusively, by B Braun
Melsungen in Germany and traded under the name
Lyodura. Over 100 Japanese cases, and all but one of the
UK cases (the source of the first case identified in the UK is
unknown), have been associated with this particular product
and only rarely has dura processed by other manufacturers
been associated with transmission.18 19 Although the first case
in the UK was exposed to potentially infectious dura in 1969,
a disproportionately large number of cases were exposed
between 1983 and 1987 (80% of those identified worldwide
and six of the seven cases in the UK). Interestingly, the
apparent reduction in the number of cases post-1987
coincided with the introduction of stringent donor selection
criteria and the introduction of sodium hydroxide immersion
techniques in the manufacturing process.
We found no temporal or geographical association between
any of the dura-associated cases, or any other case of CJD
identified in the UK, despite potential contamination of
neurosurgical instruments.
It has been proposed that clinical features at onset are
dependent on the site of graft placement or underlying
parenchymal damage20–22 and our findings may support such
a proposition. The explanation for this observation is unclear.
We, could, speculate that the pathological process starts
within a region adjacent to the graft and that this is reflected
in the early clinical features. This proposition may also be
supported by findings obtained at autopsy, with severe
pathological changes identified adjacent to graft placement
in three cases. Overall, the pathology is consistent for that
previously described in dura mater-associated CJD.9 18 We did
not identify either ‘‘kuru-type’’ or florid PrP plaques. The
florid PrP plaques were previously noted in limited distribu-
tion in a small number of dural graft-associated iatrogenic
CJD cases in Japan.21 23 24
We believe case VIII represents the first reported case of
CJD in a person previously exposed to a graft from a non-
human source. The age at onset, duration of illness, clinical
and investigative features were similar to a typical case of
sporadic CJD. Furthermore, the pathological features were
also considered characteristic of sporadic CJD, with type 1
PrPres identified. Neither finding can definitively exclude the
possibility of transmission of a yet unidentified pathogen. As
natural transmissible spongiform encephalopathies are,
however, as yet unrecognised in pigs, despite experimental
transmission in animal models,25 a chance association seems
the most plausible explanation.
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Table 1 UK case details—human dura mater
Case Surgical procedure Dura
Year of
surgery
Year of
death
Incubation
period (Months)
Duration of
illness (Months)
I, Esmonde et al12 Suboccipital craniotomy and C1/2
laminectomy for cerebellar ectopia and
syringomyelia
? 1969 1979 104* 6
II, Esmonde et al12 Excision of a left temporal cortex
meningioma
L 1983 1991 93* 5*
III Repair surgical leak after acoustic
neuroma excision
L 1985 1989 51 2
IV, Willison et al13 Posterior fossa decompression and
cervical laminectomy for cerebellar
ectopia or syringomyelia
L 1985 1989 45* 4
V Excision of a left parietal cortex
meningioma
1:L 1985 1993 1:86 11
2:L 1986 2:79
VI Excision of a cerebellar astrocytoma L 1986 1997 103 33
VII Excision of an eosinophilic
granuloma right frontal region skull
L 1987 2003 177 5
Porcine dura graft:
VIII Excision of a right frontoparietal
meningioma
P 1988 2000 134 3
*Revised from previously published figures.
L, Lyodura; P, Porcine dura.
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